Neratinib enhances trastuzumab emtansine trafficking and antitumor activity in breast cancer models

Purpose The efficacy of trastuzumab emtansine (T-DM1) relies on HER2 binding, internalization, intracellular processing, and payload delivery. We investigated how neratinib and tucatinib differentially affect T-DM1 trafficking and antitumor activity in breast cancer models. Methods HER2-expressing breast cancer cells were treated with T-DM1 alone or in combination with neratinib or tucatinib, and cell viability was assessed by CCK-8 assay. pHrodo-labeled T-DM1 was used to quantify acidification-associated intracellular accumulation. HER2 phosphorylation and HER2-associated ubiquitination were examined by immunoblotting and immunoprecipitation. Antitumor activity was evaluated in HCC1954 orthotopic xenografts. Results Neratinib enhanced T-DM1-mediated viability reduction from 51.7% to 31.0% in SK-BR-3 cells and from 37.4% to 19.3% in HCC1954 cells. In contrast, tucatinib did not significantly augment T-DM1 activity. Neratinib increased the pHrodo-T-DM1 fluorescence index and HER2-associated ubiquitin signal, while both kinase inhibitors reduced HER2 phosphorylation. Dynasore, an inhibitor of dynamin-dependent endocytosis, reduced pHrodo fluorescence and partially reversed the observed viability loss. In cells with lower ERBB2 transcript expression, the combination effects were modest. In xenografts, T-DM1 combined with neratinib significantly reduced tumor growth compared to T-DM1 alone and was associated with reduced HER2-pathway phosphorylation and increased caspase-3 cleavage. Conclusion We demonstrate that neratinib may potentiate T-DM1 activity, which is associated with increased accumulation in acidic compartments and increased HER2-associated ubiquitination. These findings support further evaluation of neratinib as a combination partner with T-DM1, particularly regarding productive payload delivery and treatment scheduling.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-19
DOI
https://doi.org/10.21203/rs.3.rs-11496490/v1
Primary Topic
HER2/EGFR in Cancer Research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Neratinib enhances trastuzumab emtansine trafficking and antitumor activity in breast cancer models

Ming‐Jen Chen, Shao-Chiang Chang, Meng-Ching Yeh, Yuan-Ching Chang et al.
Research Square
HER2/EGFR in Cancer Research
preprint

Neratinib enhances trastuzumab emtansine trafficking and antitumor activity in breast cancer models

Ming‐Jen Chen, Shao-Chiang Chang, Meng-Ching Yeh, Yuan-Ching Chang, Shih-Ping Cheng
preprint en

Abstract

Purpose The efficacy of trastuzumab emtansine (T-DM1) relies on HER2 binding, internalization, intracellular processing, and payload delivery. We investigated how neratinib and tucatinib differentially affect T-DM1 trafficking and antitumor activity in breast cancer models. Methods HER2-expressing breast cancer cells were treated with T-DM1 alone or in combination with neratinib or tucatinib, and cell viability was assessed by CCK-8 assay. pHrodo-labeled T-DM1 was used to quantify acidification-associated intracellular accumulation. HER2 phosphorylation and HER2-associated ubiquitination were examined by immunoblotting and immunoprecipitation. Antitumor activity was evaluated in HCC1954 orthotopic xenografts. Results Neratinib enhanced T-DM1-mediated viability reduction from 51.7% to 31.0% in SK-BR-3 cells and from 37.4% to 19.3% in HCC1954 cells. In contrast, tucatinib did not significantly augment T-DM1 activity. Neratinib increased the pHrodo-T-DM1 fluorescence index and HER2-associated ubiquitin signal, while both kinase inhibitors reduced HER2 phosphorylation. Dynasore, an inhibitor of dynamin-dependent endocytosis, reduced pHrodo fluorescence and partially reversed the observed viability loss. In cells with lower ERBB2 transcript expression, the combination effects were modest. In xenografts, T-DM1 combined with neratinib significantly reduced tumor growth compared to T-DM1 alone and was associated with reduced HER2-pathway phosphorylation and increased caspase-3 cleavage. Conclusion We demonstrate that neratinib may potentiate T-DM1 activity, which is associated with increased accumulation in acidic compartments and increased HER2-associated ubiquitination. These findings support further evaluation of neratinib as a combination partner with T-DM1, particularly regarding productive payload delivery and treatment scheduling.

Research Square
Mackay Memorial Hospital (TW)
HER2/EGFR in Cancer Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon